The PROTAC milestone: FDA approval of vepdegestrant (ARV-471) for ESR1 -mutated breast cancer

Biochimica et Biophysica Acta: Biomembranes · Elsevier

Аннотация

Publication date: September 2026 Source: Drug Discovery Today, Volume 31, Issue 5 Author(s): Xin Lin, Hua Xiang, Guoshun Luo

Читать у издателя →

Похожие статьи